Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure

Fig. 1

Flow cytometric appearance of CliniMACS Plus or Prodigy generated CD34 selection products: excerpts from the flow cytometric analysis (quality control) of the final products from all three runs are depicted; in all cases 100,000 CD45 + events (WBC) were acquired. For Prodigy and CliniMACS Plus, respectively, the left panels show SSC over CD34; besides CD34+ target cells (orange), SSC-intermediate, CD34-negative monocytes (blue) and within the lymphocyte region (SSC-low, CD34-negative), T-cells (red) are visible. The right panels depict CD45+ CD3+ events for Prodigy and CliniMACS Plus, respectively. The greater content of monocytes and T-cells in Prodigy products is readily visible. Corresponding numbers are given in Table 1

Back to article page
\